Introduction
============

COPD is characterized by chronic airflow obstruction related to airway inflammation, remodeling, and parenchymal destruction of the lung.[@b1-copd-13-3529] This causes dyspnea, exercise limitation, and an impaired quality of life. Worldwide, more than 200 million tourists are estimated to visit altitudes over 1,500 m each year.[@b2-copd-13-3529] Among them, many patients with COPD are expected to experience adverse health effects including acute mountain sickness,[@b3-copd-13-3529] excessive dyspnea, and impairment of exercise performance during everyday activities when exposed to hypobaric hypoxia during altitude sojourns. However, whether and to which extent impaired pulmonary gas exchange, reduced muscle strength, and cardiovascular and other limitations affect well-being and physical performance in COPD patients traveling to high altitude has not been extensively studied. In a recent physiological investigation, we observed a reduction of submaximal constant load bicycle exercise by about one half due to systemic and cerebral hypoxemia in a group of COPD patients at 2,590 m compared with the performance at their low altitude residence.[@b4-copd-13-3529] To provide a scientific basis to counsel COPD patients planning altitude sojourns, the current study evaluated the effect of travel to altitudes of 1,650 and 2,590 m for a total of 4 days on exercise performance, general well-being, and several other outcomes in lowlanders with moderate to severe COPD.

Methods
=======

Study design and setting
------------------------

This randomized crossover trial evaluated the effect of a 4-day sojourn at moderate altitude on exercise performance, symptoms, and several physiological outcomes in patients with stable COPD, Global Initiative for Obstructive Lung Disease (GOLD) grades 2--3, living below 800 m. The studies were performed from June to August 2013 in Zurich (490 m, 1,608 ft, barometric pressure \[PB\] 719 Torr) and in Swiss alpine villages, Davos Clavadel (1,650 m, 5,413 ft, PB 628 Torr) and Davos Jakobshorn (2,590 m, 8,497 ft, PB 562 Torr). Participants spent 2 days at each study location, in random order, to undergo outcome assessments. Some physiological outcomes evaluating gas exchange, cerebral blood flow, and cerebral and muscle tissue oxygenation as a part of the current trial have been reported recently.[@b4-copd-13-3529] Apart from baseline characteristics of study participants, the data presented here have not been published except previously in abstract form. The study was approved by the Cantonal Ethics Committee of Zurich (EK-2013-0088), subjects gave written informed consent, and the trial is registered at [www.ClinicalTrials.gov](http://www.clinicalTrials.gov): NCT01875133.

Participants
------------

Subjects with stable COPD, GOLD grade 2--3, diagnosed according to the GOLD guidelines (forced expiratory volume in 1 second \[FEV~1~\]/forced vital capacity \[FVC\] ratio \<0.7, FEV~1~ between 30% and 80% predicted), aged 18 to 75 years, both sexes, living below 800 m, were invited to participate. Subjects with very severe COPD (FEV~1~ \<30% predicted), respiratory failure at lowland (PaO~2~ \<7.3 kPa or PaCO~2~ \>6.0 kPa), or those with known previous intolerance of altitude 2,600 m or lower, a history of sleep apnea syndrome, or more than mild or inadequately controlled cardiovascular disease were excluded. Patients having traveled to altitudes \>1,500 m for \>2 days within 4 weeks prior to the study were also excluded.

Randomization and intervention
------------------------------

Using a balanced block design, participants were randomized to one of the following four sequences of altitude exposure with sojourns of 2 days at each location: Group A 490/1,650/2,590 m; Group B 490/2,590/1,650 m; Group C 1,650/2,590/490 m; Group D 2,590/1,650/490 m. Participants traveled by train and car between Zurich and Davos Clavadel and by cable car between Davos Clavadel and Davos Jakobshorn.

As a safety precaution, the protocol required that any patient with intolerable discomfort (according to the patient's own subjective assessment), symptoms or signs of relevant intercurrent illness, such as a COPD exacerbation, new onset or unstable cardiovascular disease including uncontrolled hypertension (systolic and/or diastolic blood pressure \>220 and/or \>110 mmHg), neurological impairment, gastrointestinal symptoms requiring treatment, or severe hypoxemia (arterial oxygen saturation \<80% for \>30 minutes) were withdrawn from the study, treated with oxygen and other measures as appropriate, and transported to low altitude. Maximal bicycle exercise tests to exhaustion were performed at 490 m and 1,650 m, but for safety reasons, not at 2,590 m. Patients were asked to continue their regular medication during the study.

Assessments
-----------

### Exercise tests, pulmonary function, and arterial blood gas analysis

Six-minute walk tests with monitoring of pulse oximetry (SpO~2~) were performed.[@b5-copd-13-3529]

Lung function studies including spirometry, body plethysmography (only at 490 and 2,590 m due to logistical constraints), diffusing capacity (Bodystik™ and Diffustik™, Geratherm Respiratory GmbH, Bad Kissingen, Germany), and nasal sniff inspiratory pressure (Morgan P max, Morgan Medical Ltd., Gillingham, UK) were performed 15 minutes after inhalation of a short-acting bronchodilator.[@b6-copd-13-3529],[@b7-copd-13-3529] Pulmonary volumes and flows were expressed in body temperature, pressure, and saturated conditions. Diffusing capacity was measured by the single-breath technique. To allow for convenient comparisons between values measured at 490 m, 2,590 m, and predicted values for sea level, values measured at 2,590 m were corrected for the lower PB at altitude by transforming the equation recommended to predict values at high altitude:[@b8-copd-13-3529] $$\begin{matrix}
{\lbrack\text{DLCO}_{\text{altitude}} = ~\text{DLCO}_{\text{sea}\ \text{level}}/(1 + 0.00031*\lbrack\text{PI},\ O_{2} - 150{\rbrack\left. ) \right\rbrack},\ } \\
{\text{and}\ \text{solving}\ \text{for}\ \text{DLCO}_{\text{sea}\ \text{level}},} \\
\end{matrix}$$ $$\begin{matrix}
{\lbrack\text{DLCO}_{\text{sea}\ \text{level}} = ~\text{DLCO}_{2,590\ m}*(1 + 0.00031*\lbrack\text{PI},\ O_{2} - 150{\rbrack\left. ) \right\rbrack},\ } \\
{\text{whereas}\ \text{PI},\ O_{2}\ \text{at}\ 2,590\ m\ \text{corresponds}\ \text{to}\ } \\
{108\ \text{mmHg}.} \\
\end{matrix}$$

Cardiopulmonary cycle exercise tests were performed with a progressive ramp protocol to exhaustion[@b9-copd-13-3529] at 490 m and 1,650 m. The target duration of the exercise test at 490 m was 8--12 minutes, and the slope (ie, increase in watts per minute) was selected accordingly, based on the individually predicted maximal work rate (*W*max). For each individual, an identical ramp protocol was applied at 490 m and 1,650 m. Ventilation, gas exchange, oxygen saturation, and electrocardiogram were recorded breath by breath (Ergostik™, Geratherm Respiratory GmbH). Radial artery blood was drawn at rest and during maximal exercise and analyzed immediately (RAPIDPOINT 405, Siemens Healthcare Diagnostics GmbH, Zurich, Switzerland). Maximal physiologic variables of exercise tests were defined as mean values during the final 30 seconds of maximal exercise. Patients indicated the perceived exertion on the Borg CR10 scale.[@b10-copd-13-3529]

### Clinical examination, evaluation of acute mountain sickness (AMS), and dyspnea

A complete medical history was obtained. Physical examination included weight, height, blood pressure, pulse rate, and SpO~2~. Dyspnea was assessed by the modified Medical Research Council dyspnea score.[@b11-copd-13-3529] AMS was assessed in the morning and evening by the Environmental Symptoms Questionnaire cerebral score (AMSc) comprising 11 questions on AMS symptoms rated from 0 (not at all) to 5 (extreme). The weighted sum of responses ranges from 0 to 5. Scores ≥0.7 are considered to reflect clinically relevant AMS.[@b12-copd-13-3529]

Outcomes
--------

The primary outcome was the change in the 6-minute walk distance (6MWD). Secondary outcomes were the oxygen saturation by SpO~2~, heart rate, lung function, arterial blood gases, and measures derived from cardiopulmonary exercise testing.

Sample size
-----------

Sample size estimation indicated that at least 36 participants were required to detect a minimally important difference in the 6MWD of 30 m (SD 55 m) with a power of 80%, alpha 0.05.[@b13-copd-13-3529] To account for dropouts, 40 participants were included.

Blinding
--------

Investigators analyzing the data were blinded to altitude and altitude exposure sequence.

Statistical analysis
--------------------

Due to non-normal distribution of the majority of the data, all variables were summarized by medians and quartiles. Overall effects were evaluated by Friedman ANOVA, and significant findings were further analyzed by post hoc analyses using Wilcoxon matched pairs tests. Effects of altitude exposure were evaluated by computing mean differences in outcomes with 95% CIs. The primary outcome was analyzed according to the intention-to-treat principle with missing data replaced by multiple imputations applying a multivariable regression model with baseline variables as independent predictors. Secondary outcomes were analyzed according to the per-protocol principle on all available data. Regression analyses were used to separately assess the effect of altitude (1,650 m and 2,590 m vs 490 m) on the 6MWD while controlling for baseline characteristics and potential confounders. Age, sex, and all predictor variables for which univariate analysis revealed an association with *P*\<0.2 were entered into a subsequent multivariable model. A probability of *P*\<0.05 was considered as statistically significant.

Results
=======

The study participant flow is shown in [Figure 1](#f1-copd-13-3529){ref-type="fig"}. Of 191 screened subjects, 139 refused to participate and 12 met exclusion criteria. Thus, 40 subjects were included and randomized and their primary outcome (6MWD) was analyzed according to the intention-to-treat principle. One patient each in groups A to C and two in group D required nocturnal supplemental oxygen because of severe hypoxemia (as defined per protocol by a value of SpO~2~ \<80% for ≥30 minutes) or dyspnea. These subjects felt well thereafter and remained at altitude but were excluded from exercise tests on the next day. Two subjects withdrew informed consent after baseline examination in Zurich and one refused to ascend to 2,590 m because of insomnia at 1,650 m. Thus, the per-protocol group consisted of 32 participants ([Table 1](#t1-copd-13-3529){ref-type="table"}). The age of patients ranged from 51 to 74 y, 25% were current smokers, and the median FEV~1~ was 59% predicted. The most prevalent comorbidities were cardiovascular diseases. The majority of participants (81%) used regular inhaled β-adrenergics or anticholinergics and 56% used inhaled glucocorticoids ([Table 1](#t1-copd-13-3529){ref-type="table"}).

Several participants experienced altitude-related adverse health effects. In addition to those mentioned above who were withdrawn because of severe hypoxemia, dyspnea, or other discomfort, patients had (on average) mild symptoms of AMS that were most pronounced on the first day at 2,590 m ([Table 2](#t2-copd-13-3529){ref-type="table"}). The incidence of clinically relevant AMS (AMSc score ≥0.7) on the first and second day at 1,650 m was 3% (1 out of 38) and 0%, and on the first and second day at 2,590 m was 5% (2 out of 38) and 0% in patients ascending to higher altitudes. The combined incidence of any altitude-related adverse health effect during the 4 days at altitude was 24% (9 out of 38).

Six-minute walk tests, pulmonary function, and arterial blood gases
-------------------------------------------------------------------

The 6MWD and SpO~2~ at the beginning and end of the 6-minute walk test were significantly reduced at 1,650 m and 2,590 m compared with those at 490 m, and the perceived dyspnea at the end of the 6MWD was greater at higher altitudes compared with values at 490 m ([Table 2](#t2-copd-13-3529){ref-type="table"} and [Figure 2](#f2-copd-13-3529){ref-type="fig"}).

Univariable regression analysis with the change in the 6MWD from 490 m baseline as the dependent variable revealed that altitude, second vs first day at altitude, the 6MWD, FEV~1~, and DLCO at 490 m were significant predictors. In a multivariable analysis, maintaining age, sex, and variables with *P*\<0.2 in univariable analysis in the model, significant independent predictors for the 6MWD were altitude 1,650 m (predicted mean change −17 m \[95% CI −27 to −6 m\], *P*=0.001) and 2,590 m (predicted mean change −37 m \[95% CI −47 to −27 m\], *P*\<0.001). Additional independent predictors were the baseline value of the 6MWD (+0.8 m \[+0.7 to +0.9\], *P*\<0.001) and FEV~1~ % predicted at 490 m (+0.9 m \[+0.1 to +1.7\], *P*=0.029), while age (*P*=0.866), sex (*P*=0.333), and DLCO at 490 m (*P*=0.188) were not.

Spirometry revealed no significant changes in FVC and FEV~1~ (in liters) nor in their ratio over the course of the study at the different altitudes ([Table 3](#t3-copd-13-3529){ref-type="table"}). FVC (in % predicted) tended to be minimally greater at 1,650 m compared with other altitudes. Static lung volumes (total lung capacity, residual volume) were not different at 2,590 m vs 490 m. Peak expiratory flow improved significantly with increasing altitude, and correspondingly, airway resistance was reduced at 2,590 m vs 490 m. There was a slight but statistically significant reduction in the DLCO corrected for hemoglobin and for the reduced PB at 2,590 m.

The arterial blood gas analysis revealed a mild to moderate hypoxemia that increased with altitude ([Figure 2](#f2-copd-13-3529){ref-type="fig"}, [Table 4](#t4-copd-13-3529){ref-type="table"}). The alveolar--arterial PO~2~ gradient was elevated at 490 m and decreased slightly at higher altitudes but remained elevated. According to inclusion criteria, patients were normocapnic at 490 m and their PaCO~2~ was slightly reduced at higher altitudes with an associated increase in pH.

Cardiopulmonary exercise tests
------------------------------

Compared with 490 m, endurance time, *W*max, and maximal oxygen uptake (V′O~2~ normalized for weight) were all significantly reduced at 1,650 m. The reduction in endurance time and thus *W*max was −7% (95% CI −13 to 0, *P*\<0.01). The impairment in exercise performance at 1,650 m was associated with a reduced PaO~2~, SaO~2~, and alveolar--arterial PO~2~ gradient during maximal exercise; in addition, there was a lower PaCO~2~ and increased ventilatory equivalents for O~2~ uptake and CO~2~ output (V′E/O~2~ and V′E/CO~2~) compared with 490 m. Subjective perception of dyspnea and leg fatigue were similar at low and high altitude ([Table 5](#t5-copd-13-3529){ref-type="table"}).

Discussion
==========

The results of the current randomized trial show that patients with moderate to severe COPD living below 800 m experienced a mild reduction in the 6MWD by a mean of 41 m at 2,590 m and by 22 m at 1,650 m. At 1,650 m, bicycle exercise tests revealed a mild reduction of maximal performance by 7% related to hypoxemia and ventilatory limitation. Over the course of the 4-day sojourn at higher altitude, 9 of the 38 patients (24%) experienced symptoms of AMS, dyspnea, or severe hypoxemia that required oxygen therapy for safety reasons. The current results represent a valuable reference that might help to counsel COPD patients planning altitude travel and prevent adverse effects on their health.

Data on exercise performance of COPD patients traveling to altitude are scant. In a study by Kelly et al,[@b14-copd-13-3529] 18 COPD patients (mean FEV~1~ 42% predicted) were transported by car from sea level to Mt Hutt (2,086 m) for a sojourn of few hours. Not all patients were able to complete the 6-minute walk, and their mean walk distance was reduced to less than half of that at sea level (from 467 to 245 m). In eight COPD patients (FEV~1~ 25%--78% predicted) traveling from sea level to Mount Washington (1,920 m), Vermont, PaO~2~ initially dropped from 8.8 to 6.8 kPa, but values increased to 7.3 kPa with acclimatization over 4 days; patients performed mild treadmill exercise without notable problems.[@b15-copd-13-3529] In the Dutch Asthma Center Davos (1,560 m), 37 lowlanders with COPD (FEV~1~ 63% predicted) underwent a 5-week rehabilitation training. Compared with baseline evaluation at sea level, their exercise capacity at arrival at 1,560 m was not significantly reduced and it increased over the course of rehabilitation.[@b16-copd-13-3529] No other studies on exercise performance during intermediate or long-term altitude sojourns of COPD patients were identified.

Compared with the patients reported by Kelly et al,[@b14-copd-13-3529] the participants in the current trial had a less pronounced reduction in the 6MWD, which might be due to less severe COPD in the current trial (FEV~1~ 59% vs 42% predicted). Another explanation is the difference in the study design because half of the patients in the current trial already stayed for 2 days at 1,650 m before ascending further to 2,590 m ([Figure 1](#f1-copd-13-3529){ref-type="fig"}), which might have led to improved physical performance at 2,590 m by acclimatization.

We have previously reported a reduction of endurance time during submaximal cycle exercise by 54% in COPD patients at 2,590 m.[@b4-copd-13-3529] Underlying mechanisms were combined effects of hypobaric hypoxia on dyspnea and pulmonary gas exchange with arterial and cerebral hypoxemia (measured by near-infrared spectroscopy), while ventilatory limitation seemed not to have played a predominant role. Because exercise intensity during a 6MWD is submaximal, we assume that similar mechanisms may have contributed to the impaired performance at higher altitudes compared with 490 m in COPD patients participating in the current study. In turn, during progressive maximal ramp exercise at 1,650 m, our results suggest that mechanical ventilatory limitation has contributed to the reduction in maximal work performance. Thus, the breathing reserve was reduced, and there was a greater ventilatory inefficiency evidenced by the increased ventilatory equivalents for both O~2~ uptake and CO~2~ output ([Table 3](#t3-copd-13-3529){ref-type="table"}).

In the current patients, there were no relevant changes in static and dynamic lung volumes at 2,590 vs 490 m ([Table 3](#t3-copd-13-3529){ref-type="table"}). For comparison, previous studies in healthy individuals[@b17-copd-13-3529] and in patients with obstructive sleep apnea syndrome[@b18-copd-13-3529] ascending to 2,590 m have shown a slight reduction in FVC that was not associated with a change in inspiratory muscle strength and was therefore possibly related to subclinical interstitial fluid accumulation. In the current study, a larger interindividual variability of baseline lung function in the COPD patients may have reduced the power to detect minor, altitude-induced changes. However, the current patients having an already reduced diffusing capacity to nearly half of the predicted value at 490 m revealed a further decrease at 2,590 m ([Table 3](#t3-copd-13-3529){ref-type="table"}). This was associated with an increase in body weight, suggesting a possible interstitial pulmonary fluid accumulation as suspected in healthy individuals in previous studies.[@b19-copd-13-3529],[@b20-copd-13-3529]

In addition to the impairment of pulmonary gas exchange and consecutive hypoxemia related to the airflow limitation and parenchymal destruction of the lung, a potential further cause of exercise limitation in COPD patients at altitude relates to an excessive rise in pulmonary artery pressure due to hypoxic vasoconstriction in the presence of some degree of preexisting pulmonary hypertension. In support of this hypothesis, echocardiographic studies performed at rest revealed an elevated pulmonary artery pressure at 2,590 m compared with that at 490 m.[@b21-copd-13-3529]

In this trial, 9 of the 38 randomized patients (24%) ascending to higher altitude suffered from adverse altitude-related health effects including headaches and clinically relevant symptoms of AMS (5% at 1,650 m, 18% at 2,590 m), and 13% had severe hypoxemia at 2,590 m that prompted us to administer supplemental oxygen. While symptoms of AMS might have been controlled by pain suppressants and other drugs including acetazolamide or dexamethasone that are successfully used in healthy mountaineers suffering from AMS,[@b22-copd-13-3529] we considered it unethical to expose the COPD patients to prolonged hypoxemia with SpO~2~\<80%. The rules for administration of oxygen were arbitrary because there is no conclusive evidence to suggest that level and duration of hypoxemia represent an increased risk for COPD patients, some of them with cardiovascular comorbidities. It is conceivable, however, that the risk for relevant cardiac arrhythmias and possibly adverse cardiovascular events might have been elevated at 2,590 m because we have previously observed a prolongation of the QT interval in patients with COPD during a stay at 2,048 m[@b23-copd-13-3529] or with obstructive sleep apnea syndrome at 2,590 m.[@b24-copd-13-3529] Moreover, we suspect that those COPD patients who had severe hypoxemia would have developed more severe symptoms of AMS if they had stayed untreated at altitude for a longer time.

According to our study design, the order of exposure to the different altitudes was performed in random order to reduce the bias that might have been induced by a fixed sequence of stay at the three elevations. The fact that half of the patients had already spent 2 days at a higher altitude than that of their residence before assessments at 1,650 or 2,590 m, respectively ([Figure 1](#f1-copd-13-3529){ref-type="fig"}), is a limitation that might have influenced the incidence of AMS and other altitude-related adverse health effects by acclimatization. In particular, we cannot exclude that a direct ascent from 490 m to 2,590 m by all participants might have resulted in a higher incidence of AMS and other adverse outcomes. However, in multivariable regression analysis, the altitude exposure sequence was not an independent predictor of the 6MWD. Although a relatively large number of well-characterized COPD patients participated in the current study, it included patients with moderate to severe COPD only; therefore, our results might not apply to patients with very severe (FEV~1~\<30% predicted) or only mild (FEV~1~\>80% predicted) COPD.

Conclusion
==========

The results of the current study demonstrate that lowlanders with moderate to severe COPD experience a modest decrease in the 6MWD when ascending for 2 days to 1,650 m and 2,590 m and their maximal performance during bicycle exercise is decreased at 1,650 m due to hypoxemia and ventilatory limitation. Severe hypoxemia for prolonged time was prevented by oxygen administration. Therefore, more severe impairments and adverse health effects might have been avoided. Our data may serve as a valuable basis for counseling patients with COPD planning altitude travel taking the individual condition, the physical fitness, and comorbidities into account.
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![Patient flow.\
**Notes:** Of 191 eligible subjects, 40 were randomized into one of the four altitude exposure sequences (A--D) and included in the intention-to-treat analysis. Data from 32 subjects were included in the per-protocol analysis.](copd-13-3529Fig1){#f1-copd-13-3529}

![Altitude-induced changes.\
**Notes:** Dots represent mean differences and horizontal bars the 95% CIs, values are numerically indicated on the right. Altitude effect is significant when the zero value is not part of the 95% CI.](copd-13-3529Fig2){#f2-copd-13-3529}

###### 

Characteristics of patients

  Characteristic                                               At baseline
  ------------------------------------------------------------ -------------------
  Demographics and clinical characteristics                    
   n, (men/women)                                              32 (19/13)
   Age, y                                                      67 (60; 70)
   Current smokers, n (%)                                      8 (25)
   Smoking, pack-years                                         43 (20; 69)
   FEV~1~, % predicted (postbronchodilator)                    59 (51; 71)
   GOLD grade 2, n (%)                                         20 (63)
   GOLD grade 3, n (%)                                         12 (37)
   Body mass index, kg/m^2^                                    27.1 (22.2; 29.2)
   mMRC score                                                  1.0 (1.0; 1.5)
   mMRC score ≥2, n (%)                                        8 (25)
  Comorbidities, n patients (%)                                
   Arterial hypertension                                       19 (59)
   Coronary artery disease and other cardiovascular diseases   8 (25)
   Diabetes mellitus                                           2 (6)
   Depression                                                  8 (25)
   Previous pulmonary embolism                                 2 (6)
   Dyslipidemia                                                9 (28)
  Medication, n patients (%)                                   
   Inhalation of topical corticosteroids                       18 (56)
   Inhalation of β-adrenergics                                 26 (81)
   Inhalation of anticholinergics                              26 (81)
   Roflumilast                                                 1 (3)
   Diuretics                                                   7 (22)
   ACE-inhibitor or AT2 antagonist                             17 (53)
   β-blocker                                                   8 (25)
   Calcium channel blocker                                     6 (19)
   Lipid-lowering therapy                                      7 (22)
   Antidiabetics                                               2 (6)
   Antidepressants                                             7 (22)
   Theophylline                                                1 (3)
   Antiplatelet therapy                                        7 (22)
   Oral anticoagulation                                        3 (9)
   Antiarrhythmic therapy                                      1 (3)

**Note:** Values presented as median (quartiles) unless indicated otherwise.

**Abbreviations:** ACE, angiotensin-converting enzyme; AT2, angiotensin II receptor; FEV~1~, forced expiratory volume in 1 second; GOLD, global initiative for chronic obstructive lung disease; mMRC, modified Medical Research Council dyspnea score; Pack-years, sum of years smoked a packet of cigarettes per day.

###### 

Six-minute walk test and clinical evaluation

                                  490 m               1,650 m                                               2,590 m                                                                                                        *P*-value                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            
  ------------------------------- ------------------- ----------------------------------------------------- -------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------
  6-minute walk distance, m       534±93              547±93[\*](#tfn4-copd-13-3529){ref-type="table-fn"}   512±93[\*](#tfn4-copd-13-3529){ref-type="table-fn"},[\#](#tfn5-copd-13-3529){ref-type="table-fn"}              525±93[\#](#tfn5-copd-13-3529){ref-type="table-fn"},[†](#tfn6-copd-13-3529){ref-type="table-fn"}                                                         491±93[\*](#tfn4-copd-13-3529){ref-type="table-fn"},[\#](#tfn5-copd-13-3529){ref-type="table-fn"},[†](#tfn6-copd-13-3529){ref-type="table-fn"},[‡](#tfn7-copd-13-3529){ref-type="table-fn"}              504±93[\#](#tfn5-copd-13-3529){ref-type="table-fn"},[‡](#tfn7-copd-13-3529){ref-type="table-fn"},[¶](#tfn8-copd-13-3529){ref-type="table-fn"}                                                      \<0.001
  SpO~2~, rest, %                 94 (94; 96)         94 (93; 95)                                           92[\*](#tfn4-copd-13-3529){ref-type="table-fn"},[\#](#tfn5-copd-13-3529){ref-type="table-fn"} (91; 94)         93[\*](#tfn4-copd-13-3529){ref-type="table-fn"},[\#](#tfn5-copd-13-3529){ref-type="table-fn"} (91; 95)                                                   89[\*](#tfn4-copd-13-3529){ref-type="table-fn"},[\#](#tfn5-copd-13-3529){ref-type="table-fn"},[†](#tfn6-copd-13-3529){ref-type="table-fn"},[‡](#tfn7-copd-13-3529){ref-type="table-fn"} (88; 91)         90[\*](#tfn4-copd-13-3529){ref-type="table-fn"},[\#](#tfn5-copd-13-3529){ref-type="table-fn"},[†](#tfn6-copd-13-3529){ref-type="table-fn"},[‡](#tfn7-copd-13-3529){ref-type="table-fn"} (87; 92)   \<0.001
  SpO~2~, end of 6MWT, %          90 (84; 92)         89 (83; 92)                                           84[\*](#tfn4-copd-13-3529){ref-type="table-fn"},[\#](#tfn5-copd-13-3529){ref-type="table-fn"} (78; 87)         85[\*](#tfn4-copd-13-3529){ref-type="table-fn"},[\#](#tfn5-copd-13-3529){ref-type="table-fn"} (77; 87)                                                   78[\*](#tfn4-copd-13-3529){ref-type="table-fn"},[\#](#tfn5-copd-13-3529){ref-type="table-fn"},[†](#tfn6-copd-13-3529){ref-type="table-fn"},[‡](#tfn7-copd-13-3529){ref-type="table-fn"} (73; 82)         77[\*](#tfn4-copd-13-3529){ref-type="table-fn"},[\#](#tfn5-copd-13-3529){ref-type="table-fn"},[†](#tfn6-copd-13-3529){ref-type="table-fn"},[‡](#tfn7-copd-13-3529){ref-type="table-fn"} (73; 82)   \<0.001
  Borg dyspnea                    3.0 (2.0; 5.0)      3.0 (3.0; 4.5)                                        4.0 (2.0; 4.5)                                                                                                 4.0[\*](#tfn4-copd-13-3529){ref-type="table-fn"},[\#](#tfn5-copd-13-3529){ref-type="table-fn"},[†](#tfn6-copd-13-3529){ref-type="table-fn"} (3.0; 5.5)   3.5 (3.0; 5.0)                                                                                                                                                                                           4.0[\*](#tfn4-copd-13-3529){ref-type="table-fn"},[\#](#tfn5-copd-13-3529){ref-type="table-fn"},[†](#tfn6-copd-13-3529){ref-type="table-fn"} (3.0; 6.0)                                             0.003
  Borg leg fatigue                2.5 (2.0; 4.0)      3.0 (1.0; 5.0)                                        2.5 (1.5; 4.0)                                                                                                 3.0 (1.0; 4.0)                                                                                                                                           2.0 (0.8; 3.0)                                                                                                                                                                                           3.0 (1.5; 3.0)                                                                                                                                                                                     0.567
  mMRC dyspnea score              1 (0; 1)            1 (1; 1)                                              1 (1; 1)                                                                                                       1 (1; 1)                                                                                                                                                 1 (1; 1)                                                                                                                                                                                                 1[\#](#tfn5-copd-13-3529){ref-type="table-fn"} (1; 1)                                                                                                                                              0.045
  Acute mountain sickness score   0.00 (0.00; 0.09)   0.00 (0.00; 0.00)                                     0.00 (0.00; 0.18)                                                                                              0.00 (0.00; 0.09)                                                                                                                                        0.18[\*](#tfn4-copd-13-3529){ref-type="table-fn"},[\#](#tfn5-copd-13-3529){ref-type="table-fn"},[†](#tfn6-copd-13-3529){ref-type="table-fn"},[‡](#tfn7-copd-13-3529){ref-type="table-fn"} (0.00; 0.35)   0.00[¶](#tfn8-copd-13-3529){ref-type="table-fn"} (0.00; 0.09)                                                                                                                                      \<0.001
  Weight, kg                      77.3 (67.9; 87.4)   77.3 (68.2; 87.4)                                     78.2[\*](#tfn4-copd-13-3529){ref-type="table-fn"},[\#](#tfn5-copd-13-3529){ref-type="table-fn"} (66.6; 88.6)   78.3[\*](#tfn4-copd-13-3529){ref-type="table-fn"},[\#](#tfn5-copd-13-3529){ref-type="table-fn"} (67.4; 87.9)                                             78.3[\*](#tfn4-copd-13-3529){ref-type="table-fn"},[\#](#tfn5-copd-13-3529){ref-type="table-fn"} (67.9; 88.0)                                                                                             78.6[\*](#tfn4-copd-13-3529){ref-type="table-fn"},[\#](#tfn5-copd-13-3529){ref-type="table-fn"} (67.5; 87.9)                                                                                       \<0.001

**Notes:** Six-minute walk distance analyzed by the intention-to-treat analysis including all 40 randomized patients, values presented as mean ± SD. Other outcomes analyzed by the per-protocol approach including 32 patients, values presented as median (quartiles). *P*-values from Friedman ANOVA.

*P*\<0.05 vs 490 m day 1,

*P*\<0.05 vs 490 m day 2,

*P*\<0.05 vs 1,650 m day 1,

*P*\<0.05 vs 1,650 m day 2,

*P*\<0.05 vs 2,590 m day 1.

**Abbreviations:** 6MWT, 6-minute walk test; mMRC, modified Medical Research Council dyspnea score; SpO~2~, pulse oximetry.

###### 

Pulmonary function

                                                                                    490 m               1,650 m             2,590 m                                                                                                          *P*-value                                                                                                                                                                                                                                                                                                                                          
  --------------------------------------------------------------------------------- ------------------- ------------------- ---------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------- ---------
  FVC, L                                                                            3.3 (3.0; 3.9)      3.5 (3.1; 4.2)      3.4 (3.1; 4.2)                                                                                                   3.4 (3.0; 3.9)                                                                                                   3.3 (3.1; 4.1)                                                                                                   3.4 (3.2; 4.1)                                                                                                   0.199
  FVC, % pred                                                                       92 (88; 109)        95 (90; 113)        99[\*](#tfn11-copd-13-3529){ref-type="table-fn"} (89; 111)                                                       97 (91; 107)                                                                                                     95[†](#tfn13-copd-13-3529){ref-type="table-fn"} (88; 105)                                                        94[†](#tfn13-copd-13-3529){ref-type="table-fn"} (88; 104)                                                        0.034
  FEV~1~, L                                                                         1.5 (1.3; 2.1)      1.6 (1.4; 2.1)      1.7 (1.4; 2.2)                                                                                                   1.6 (1.4; 2.1)                                                                                                   1.5 (1.4; 2.2)                                                                                                   1.6 (1.4; 2.2)                                                                                                   0.231
  FEV~1~, % pred                                                                    59 (51; 71)         57 (52; 75)         62 (58; 73)                                                                                                      63 (55; 71)                                                                                                      57 (53; 69)                                                                                                      56 (54; 72)                                                                                                      0.107
  FEV~1~/FVC, %                                                                     51 (47; 62)         51 (47; 63)         53 (46; 61)                                                                                                      53 (48; 62)                                                                                                      53 (46; 61)                                                                                                      53 (45; 61)                                                                                                      0.283
  PEF, L                                                                            4.73 (3.96; 6.19)   4.73 (3.76; 6.24)   4.95[\*](#tfn11-copd-13-3529){ref-type="table-fn"},[\#](#tfn12-copd-13-3529){ref-type="table-fn"} (4.08; 6.49)   5.20[\*](#tfn11-copd-13-3529){ref-type="table-fn"},[\#](#tfn12-copd-13-3529){ref-type="table-fn"} (4.23; 6.70)   4.88[†](#tfn13-copd-13-3529){ref-type="table-fn"},[‡](#tfn14-copd-13-3529){ref-type="table-fn"} (3.93; 6.14)     4.95[†](#tfn13-copd-13-3529){ref-type="table-fn"},[‡](#tfn14-copd-13-3529){ref-type="table-fn"} (4.02; 6.24)     \<0.001
  PEF, % pred                                                                       68 (56; 83)         69 (55; 82)         74[\*](#tfn11-copd-13-3529){ref-type="table-fn"},[\#](#tfn12-copd-13-3529){ref-type="table-fn"} (57; 88)         72[\*](#tfn11-copd-13-3529){ref-type="table-fn"},[\#](#tfn12-copd-13-3529){ref-type="table-fn"} (62; 91)         71[†](#tfn13-copd-13-3529){ref-type="table-fn"},[‡](#tfn14-copd-13-3529){ref-type="table-fn"} (57; 84)           68[†](#tfn13-copd-13-3529){ref-type="table-fn"},[‡](#tfn14-copd-13-3529){ref-type="table-fn"} (57; 83)           \<0.001
  DLCO Hb adj, mmol[\*](#tfn11-copd-13-3529){ref-type="table-fn"} min^−1^ kPa^−1^   4.48 (3.65; 7.05)   4.52 (3.62; 7.25)   4.48 (3.47; 6.75)                                                                                                4.54 (3.46; 6.75)                                                                                                4.38[\*](#tfn11-copd-13-3529){ref-type="table-fn"},[\#](#tfn12-copd-13-3529){ref-type="table-fn"} (3.47; 6.60)   4.38[\*](#tfn11-copd-13-3529){ref-type="table-fn"} (3.65; 6.60)                                                  0.025
  DLCO Hb adj, % pred                                                               56 (45; 76)         57 (44; 76)         56 (44; 74)                                                                                                      58 (44; 75)                                                                                                      52[\*](#tfn11-copd-13-3529){ref-type="table-fn"},[\#](#tfn12-copd-13-3529){ref-type="table-fn"} (45; 74)         54[\*](#tfn11-copd-13-3529){ref-type="table-fn"} (45; 73)                                                        0.013
  TLC, L                                                                            6.8 (5.9; 7.7)      6.9 (6.2; 7.7)      --                                                                                                               --                                                                                                               6.8 (6.1; 7.7)                                                                                                   6.8 (6.1; 7.8)                                                                                                   0.984
  TLC, % pred                                                                       111 (99; 122)       110 (100; 120)      --                                                                                                               --                                                                                                               110 (100; 122)                                                                                                   111 (100; 123)                                                                                                   0.984
  RV, L                                                                             3.23 (2.72; 3.60)   3.38 (2.66; 3.69)   --                                                                                                               --                                                                                                               3.34 (2.86; 3.68)                                                                                                3.21 (2.76; 3.69)                                                                                                0.395
  RV, % pred                                                                        134 (119; 170)      139 (115; 166)      --                                                                                                               --                                                                                                               142 (121; 172)                                                                                                   136 (115; 168)                                                                                                   0.435
  RV/TLC ratio                                                                      47 (41; 54)         46 (42; 55)         --                                                                                                               --                                                                                                               47 (41; 55)                                                                                                      46 (41; 54)                                                                                                      0.371
  Raw total, kPa[\*](#tfn11-copd-13-3529){ref-type="table-fn"} s/L                  0.35 (0.26; 0.47)   0.35 (0.29; 0.47)   --                                                                                                               --                                                                                                               0.31[\*](#tfn11-copd-13-3529){ref-type="table-fn"},[\#](#tfn12-copd-13-3529){ref-type="table-fn"} (0.24; 0.41)   0.33[\*](#tfn11-copd-13-3529){ref-type="table-fn"},[\#](#tfn12-copd-13-3529){ref-type="table-fn"} (0.24; 0.44)   \<0.001
  Raw total, % pred                                                                 117 (87; 155)       117 (95; 155)       --                                                                                                               --                                                                                                               102[\*](#tfn11-copd-13-3529){ref-type="table-fn"},[\#](#tfn12-copd-13-3529){ref-type="table-fn"} (78; 135)       110[\*](#tfn11-copd-13-3529){ref-type="table-fn"},[\#](#tfn12-copd-13-3529){ref-type="table-fn"} (80; 147)       \<0.001
  SNIP, cmH~2~O                                                                     74 (59; 104)        78 (62; 94)         79 (66; 96)                                                                                                      80 (66; 101)                                                                                                     76 (51; 93)                                                                                                      81 (66; 91)                                                                                                      0.536

**Notes:** Median (quartiles), n=32. *P*-values computed by Friedman ANOVA for overall effects.

*P*\<0.05 vs 490 m day 1,

*P*\<0.05 vs 490 m day 2,

*P*\<0.05 vs 1,650 m day 1,

*P*\<0.05 vs 1,650 m day 2. DLCO Hb adj is the diffusing capacity adjusted for reduced inspiratory PO~2~ at altitude and corrected for measured hemoglobin (see Methods).

**Abbreviations:** DLCO, diffusing capacity test; FEV~1~, forced expiratory volume in 1 second; FVC, forced vital capacity; PEF, peak expiratory flow; RV, residual volume; SNIP, sniff nasal inspiratory pressure; TLC, total lung capacity.

###### 

Arterial blood gases

                                     490 m               1,650 m                                                           2,590 m                                                                                                         *P*-value
  ---------------------------------- ------------------- ----------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------- -----------
  pH                                 7.41 (7.39; 7.42)   7.44[\*](#tfn17-copd-13-3529){ref-type="table-fn"} (7.42; 7.45)   7.45[\*](#tfn17-copd-13-3529){ref-type="table-fn"},[†](#tfn18-copd-13-3529){ref-type="table-fn"} (7.43; 7.46)   \<0.001
  PaCO~2~, kPa                       5.5 (4.9; 5.9)      5.0[\*](#tfn17-copd-13-3529){ref-type="table-fn"} (4.7; 5.3)      4.9[\*](#tfn17-copd-13-3529){ref-type="table-fn"} (4.6; 5.2)                                                    \<0.001
  PaO~2~, kPa                        9.0 (8.4; 9.4)      8.1[\*](#tfn17-copd-13-3529){ref-type="table-fn"} (7.5; 8.6)      6.8[\*](#tfn17-copd-13-3529){ref-type="table-fn"},[†](#tfn18-copd-13-3529){ref-type="table-fn"} (6.3; 7.4)      \<0.001
  SaO~2~, %                          93 (93; 95)         91[\*](#tfn17-copd-13-3529){ref-type="table-fn"} (89; 92)         85[\*](#tfn17-copd-13-3529){ref-type="table-fn"},[†](#tfn18-copd-13-3529){ref-type="table-fn"} (84; 89)         \<0.001
  HCO~3~^−^, mmol/L                  25.9 (24.5; 27.4)   25.0 (24.4; 25.5)                                                 25.6[†](#tfn18-copd-13-3529){ref-type="table-fn"} (25.2; 26.8)                                                  0.006
  Base excess, mmol/L                1.2 (0.9; 2.1)      0.7[\*](#tfn17-copd-13-3529){ref-type="table-fn"} (0.1; 1.4)      0.9 (0.3; 1.8)                                                                                                  0.037
  DAaPO~2~,[@b25-copd-13-3529] kPa   4.5 (3.9; 5.4)      3.4[\*](#tfn17-copd-13-3529){ref-type="table-fn"} (2.5; 3.9)      3.1[\*](#tfn17-copd-13-3529){ref-type="table-fn"},[†](#tfn18-copd-13-3529){ref-type="table-fn"} (2.5; 3.4)      \<0.001
  Hemoglobin, g/dL                   15.0 (14.5; 15.2)   14.6 (14.1; 15.2)                                                 14.8 (14.2; 15.5)                                                                                               0.066
  Hematocrit, %                      44.5 (43.0; 44.8)   43.0[\*](#tfn17-copd-13-3529){ref-type="table-fn"} (41.0; 44.5)   43.8[†](#tfn18-copd-13-3529){ref-type="table-fn"} (42.0; 46.0)                                                  0.015

**Notes:** Median (quartiles), n=32. Arterial blood gases were drawn in the morning after the first night at the corresponding altitude. *P*-values computed by Friedman ANOVA for overall effects.

*P*\<0.05 vs 490 m day 1,

*P*\<0.05 vs 1,650 m day 1.

**Abbreviation:** DAaPO~2~, Alveolar--arterial PO~2~ difference.

###### 

Maximal exercise performance

  Values at peak exercise            490 m                                                             1,650 m
  ---------------------------------- ----------------------------------------------------------------- ------------------------------------------------------------------
  Time, min:sec                      9:13 (7:45; 10:50)                                                8:41[\*](#tfn21-copd-13-3529){ref-type="table-fn"} (6:46; 10:38)
  Work rate, watts                   92 (73; 120)                                                      82[\*](#tfn21-copd-13-3529){ref-type="table-fn"} (63; 120)
  \% predicted                       75 (59; 94)                                                       69[\*](#tfn21-copd-13-3529){ref-type="table-fn"} (59; 87)
  Heart rate, 1/min                  127 (115; 138)                                                    123 (115; 140)
  \% predicted                       80 (75; 88)                                                       80 (75; 88)
  V′O~2~, L/min                      1.21 (0.90; 1.43)                                                 1.06 (0.88; 1.47)
  \% predicted                       67 (54; 85)                                                       63 (52; 86)
  V′O~2~, mL/min/kg                  15.9 (14.2; 19.8)                                                 15.0[\*](#tfn21-copd-13-3529){ref-type="table-fn"} (12.5; 19.7)
  \% predicted                       78 (61; 85)                                                       65[\*](#tfn21-copd-13-3529){ref-type="table-fn"} (55; 90)
  V′CO~2~, L/min                     1.23 (0.90; 1.57)                                                 1.10 (0.87; 1.54)
  \% predicted                       43 (37; 52)                                                       41 (29; 55)
  Respiratory exchange ratio         1.03 (0.93; 1.09)                                                 1.03 (0.95; 1.12)
  Breath rate, L/min                 36 (29; 40)                                                       36[\*](#tfn21-copd-13-3529){ref-type="table-fn"} (32; 40)
  V′E, L/min                         52 (40; 64)                                                       53[\*](#tfn21-copd-13-3529){ref-type="table-fn"} (38; 66)
  BR, %                              20 (5; 30)                                                        12[\*](#tfn21-copd-13-3529){ref-type="table-fn"} (−3; 21)
  V′E/VO~2~                          38.4 (33.6; 45.2)                                                 42.0[\*](#tfn21-copd-13-3529){ref-type="table-fn"} (37.0; 48.3)
  V′E/VCO~2~                         37.6 (33.2; 43.8)                                                 41.0[\*](#tfn21-copd-13-3529){ref-type="table-fn"} (36.8; 47.4)
  Pulse oximetry, %                  95 (88; 98)                                                       90[\*](#tfn21-copd-13-3529){ref-type="table-fn"} (85; 95)
  Arterial pH                        7.37[\#](#tfn22-copd-13-3529){ref-type="table-fn"} (7.34; 7.39)   7.40[\*](#tfn21-copd-13-3529){ref-type="table-fn"} (7.35; 7.42)
  PaCO~2~, kPa                       5.4[\#](#tfn22-copd-13-3529){ref-type="table-fn"} (5.3; 5.8)      4.7[\*](#tfn21-copd-13-3529){ref-type="table-fn"} (4.4; 4.9)
  PaO~2~, kPa                        7.7[\#](#tfn22-copd-13-3529){ref-type="table-fn"} (7.1; 9.7)      7.5[\*](#tfn21-copd-13-3529){ref-type="table-fn"} (6.5; 8.2)
  SaO~2~, %                          92[\#](#tfn22-copd-13-3529){ref-type="table-fn"} (88; 95)         89[\*](#tfn21-copd-13-3529){ref-type="table-fn"} (83; 90)
  DAaPO~2~,[@b25-copd-13-3529] kPa   5.5[\#](#tfn22-copd-13-3529){ref-type="table-fn"} (3.6; 6.1)      3.7[\*](#tfn21-copd-13-3529){ref-type="table-fn"} (3.1; 4.6)
  Borg CR-10 dyspnea                 5 (4; 7)                                                          5 (4; 7)
  Borg CR-10 leg                     3 (2; 5)                                                          3 (1; 5)

**Notes:** Median (quartiles), n=31. Breathing reserve calculated by (MVV-V′E)/MVV^\*^100;

*P*\<0.05 vs 490 m;

Arterial blood gas analysis during maximal exercise was available in 31 patients at 1,650 m and in 12 patients at 490 m; changes in arterial blood gas between 490 and 1,650 m are presented for the 12 patients.

**Abbreviations:** BR, breathing reserve; DAaPO~2~, Alveolar--arterial PO~2~ difference; MVV, maximal voluntary ventilation; V′O~2~, oxygen uptake; V′CO~2~, carbon dioxide output; V′E, minute ventilation.

[^1]: These authors contributed equally to this work
